NO20081454L - Met-kinaseinhibitorer - Google Patents

Met-kinaseinhibitorer

Info

Publication number
NO20081454L
NO20081454L NO20081454A NO20081454A NO20081454L NO 20081454 L NO20081454 L NO 20081454L NO 20081454 A NO20081454 A NO 20081454A NO 20081454 A NO20081454 A NO 20081454A NO 20081454 L NO20081454 L NO 20081454L
Authority
NO
Norway
Prior art keywords
kinase inhibitors
met kinase
met
cancer
salts
Prior art date
Application number
NO20081454A
Other languages
English (en)
Norwegian (no)
Inventor
David Kent Williams
John S Tokarski
Xiao Tao Chen
Robert M Borzilleri
Robert F Kaltenbach
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO20081454L publication Critical patent/NO20081454L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20081454A 2005-09-30 2008-03-25 Met-kinaseinhibitorer NO20081454L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US72208905P 2005-09-30 2005-09-30
US11/529,875 US7547782B2 (en) 2005-09-30 2006-09-28 Met kinase inhibitors
PCT/US2006/038216 WO2007041379A1 (en) 2005-09-30 2006-09-29 Met kinase inhibitors

Publications (1)

Publication Number Publication Date
NO20081454L true NO20081454L (no) 2008-04-22

Family

ID=37547515

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20081454A NO20081454L (no) 2005-09-30 2008-03-25 Met-kinaseinhibitorer

Country Status (5)

Country Link
US (1) US7547782B2 (de)
EP (1) EP1937682B1 (de)
JP (1) JP2009510113A (de)
NO (1) NO20081454L (de)
WO (1) WO2007041379A1 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1934174B1 (de) * 2005-10-07 2011-04-06 Exelixis, Inc. Azetidine als mek-inhibitoren bei der behandlung proliferativer erkrankungen
JP2009529047A (ja) * 2006-03-07 2009-08-13 アレイ バイオファーマ、インコーポレイテッド ヘテロ二環系ピラゾール化合物およびその使用
CA2655128A1 (en) * 2006-06-08 2007-12-21 Array Biopharma Inc. Quinoline compounds and methods of use
AU2007338792B2 (en) 2006-12-20 2012-05-31 Amgen Inc. Substituted heterocycles and methods of use
CA2672440A1 (en) 2006-12-20 2008-07-03 Amgen Inc. Substituted heterocycles and methods of use
NZ578744A (en) * 2007-01-31 2012-02-24 Vertex Pharma 2-aminopyridine derivatives useful as kinase inhibitors
CN101730699A (zh) * 2007-03-21 2010-06-09 百时美施贵宝公司 可用于治疗增殖性、变应性、自身免疫性和炎症性疾病的稠合杂环化合物
US7776857B2 (en) * 2007-04-05 2010-08-17 Amgen Inc. Aurora kinase modulators and method of use
WO2008141130A1 (en) * 2007-05-11 2008-11-20 Kosan Biosciences, Inc. Process for the preparation of epothilones
US8030503B2 (en) 2007-05-11 2011-10-04 Kosan Biosciences Incorporated Process for the preparation of epothilones
AU2008282156B2 (en) * 2007-07-31 2014-07-17 Vertex Pharmaceuticals Incorporated Process for preparing 5-fluoro-1H-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof
US20110130406A1 (en) * 2007-09-06 2011-06-02 Array Biopharma Inc. Pyrazolo-pyridines as tyrosine kinase inhibitors
NZ585063A (en) 2007-11-02 2012-05-25 Vertex Pharma [1h- pyrazolo [3, 4-b] pyridine-4-yl] -phenyle or -pyridin-2-yle derivatives as protein kinase c-theta
WO2009094427A1 (en) 2008-01-23 2009-07-30 Bristol-Myers Squibb Company 4-pyridinone compounds and their use for cancer
US8569337B2 (en) 2008-07-23 2013-10-29 Vertex Pharmaceuticals Incorporated Tri-cyclic pyrazolopyridine kinase inhibitors
CA2731451A1 (en) 2008-07-23 2010-01-28 Vertex Pharmaceuticals Incorporated Pyrazolopyridine kinase inhibitors
JP5631310B2 (ja) 2008-07-23 2014-11-26 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ 三環式ピラゾロピリジンキナーゼ阻害剤
EP2323665B1 (de) * 2008-07-24 2013-06-19 Bristol-Myers Squibb Company Kondensierte heterozyklische verbindungen als kinase-modulatoren
AU2009279611A1 (en) 2008-08-06 2010-02-11 Vertex Pharmaceuticals Incorporated Aminopyridine kinase inhibitors
TWI491610B (zh) 2008-10-09 2015-07-11 必治妥美雅史谷比公司 作為激酶抑制劑之咪唑并嗒腈
AU2010245914A1 (en) 2009-05-06 2011-12-15 Vertex Pharmaceuticals Incorporated Pyrazolopyridines
ES2586856T3 (es) 2009-10-06 2016-10-19 Millennium Pharmaceuticals, Inc. Compuestos heterocíclicos útiles como inhibidores de PDK1
CA2787079A1 (en) 2010-01-27 2011-08-04 Vertex Pharmaceuticals Incorporated Pyrazolopyrazine kinase inhibitors
EP2528917B1 (de) 2010-01-27 2016-10-19 Vertex Pharmaceuticals Incorporated Zur behandlung von autoimmun-, entzündlichen oder (hyper)proliferativen erkrankungen geeignete pyrazolopyridine
CA2787363A1 (en) 2010-01-27 2011-08-04 Vertex Pharmaceuticals Incorporated Pyrazolopyrimidine kinase inhibitors
EP2571361A4 (de) 2010-05-19 2013-11-13 Univ North Carolina Pyrazolopyrimidinverbindungen zur krebsbehandlung
BR112014007788A2 (pt) 2011-10-03 2017-04-18 Univ North Carolina Chapel Hill compostos de pirrolopirimidina para tratamento do câncer
AU2013266438B2 (en) * 2012-05-22 2017-09-07 The University Of North Carolina At Chapel Hill Pyrimidine compounds for the treatment of cancer
BR112015008113B1 (pt) 2012-10-12 2022-05-24 Exelixis, Inc. Novo processo para preparar compostos para uso no tratamento de câncer
EP2909211A4 (de) 2012-10-17 2016-06-22 Univ North Carolina Pyrazolopyrimidinverbindungen zur krebsbehandlung
US9771330B2 (en) 2012-11-27 2017-09-26 The University Of North Carolina At Chapel Hill Pyrimidine compounds for the treatment of cancer
SG11201605207PA (en) * 2013-12-26 2016-07-28 Ignyta Inc Pyrazolo[1,5-a]pyridine derivatives and methods of their use
WO2015157123A1 (en) 2014-04-11 2015-10-15 The University Of North Carolina At Chapel Hill Mertk-specific pyrrolopyrimidine compounds
US10709708B2 (en) 2016-03-17 2020-07-14 The University Of North Carolina At Chapel Hill Method of treating cancer with a combination of MER tyrosine kinase inhibitor and an epidermal growth factor receptor (EGFR) inhibitor
WO2018197475A1 (en) 2017-04-26 2018-11-01 Basilea Pharmaceutica International AG Processes for the preparation of furazanobenzimidazoles and crystalline forms thereof
CN110218205B (zh) * 2019-07-05 2022-04-05 辽宁大学 含吡啶结构的2,4-二芳氨基嘧啶类衍生物及其应用
PE20240327A1 (es) 2021-04-13 2024-02-22 Nuvalent Inc Heterociclos con sustitucion amino para tratar canceres con mutaciones de egfr

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0119774B1 (de) 1983-03-09 1987-06-24 Beecham Group Plc Entzündungshemmende Pyrazolopyridine
EP0151962A3 (de) 1984-01-25 1985-10-02 Beecham Group Plc Pyrazolopyridin-Derivate
GB8404584D0 (en) 1984-02-22 1984-03-28 Beecham Group Plc Compounds
IE904346A1 (en) 1989-12-04 1991-06-05 Searle & Co IMIDAZO[1,2-a]PYRIDINYLALKYL COMPOUNDS FOR TREATMENT OF¹NEUROTOXIC INJURY
GB9312891D0 (en) * 1993-06-22 1993-08-04 Boots Co Plc Therapeutic agents
BR9710002A (pt) 1996-06-27 1999-08-10 Janssen Pharmaceutica Nv N-[4-(heteroarilmetil)fenil]-heteroarilaminas
ES2196806T3 (es) 1998-05-08 2003-12-16 Smithkline Beecham Plc Derivados de fenilurea y de feniltiourea.
JP2000212141A (ja) * 1999-01-13 2000-08-02 Warner Lambert Co ジアリ―ルアミン
BR9916857A (pt) 1999-01-13 2001-12-04 Warner Lambert Co 4 heteroaril diarilaminas
MXPA01011832A (es) 1999-05-21 2002-06-21 Squibb Bristol Myers Co Inhibidores de cinasas, de pirrolotriazina.
WO2001057040A1 (en) 2000-02-03 2001-08-09 Abbott Laboratories 6,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds
WO2001094353A1 (en) 2000-06-06 2001-12-13 Pfizer Products Inc. Thiophene derivatives useful as anticancer agents
JP2004522713A (ja) 2000-11-17 2004-07-29 ブリストル−マイヤーズ　スクイブ　カンパニー ｐ３８キナーゼ関連疾患の処置方法およびキナーゼインヒビターとして有用なピロロトリアジン化合物
US20020147198A1 (en) 2001-01-12 2002-10-10 Guoqing Chen Substituted arylamine derivatives and methods of use
AU2002256085A1 (en) 2001-04-06 2002-10-21 Smithkline Beecham Corporation Quinoline inhibitors of hyak1 and hyak3 kinases
US6995171B2 (en) 2001-06-21 2006-02-07 Agouron Pharmaceuticals, Inc. Bicyclic pyrimidine and pyrimidine derivatives useful as anticancer agents
GB0126902D0 (en) 2001-11-08 2002-01-02 Novartis Ag Organic compounds
TW200300350A (en) 2001-11-14 2003-06-01 Bristol Myers Squibb Co C-5 modified indazolylpyrrolotriazines
US6900208B2 (en) 2002-03-28 2005-05-31 Bristol Myers Squibb Company Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
EP1503996B1 (de) 2002-04-23 2008-12-24 Bristol-Myers Squibb Company Als kinase inhibitoren geeignete arylketonpyrrolotriazin-verbindungen
US6989451B2 (en) * 2002-06-04 2006-01-24 Valeant Research & Development Heterocyclic compounds and uses thereof
TWI329112B (en) * 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
CL2003002287A1 (es) 2002-11-25 2005-01-14 Wyeth Corp COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS
TW200420565A (en) 2002-12-13 2004-10-16 Bristol Myers Squibb Co C-6 modified indazolylpyrrolotriazines
GB0312609D0 (en) 2003-06-02 2003-07-09 Astrazeneca Ab Novel compounds
MXPA06002296A (es) 2003-08-29 2006-05-22 Pfizer Tienopiridina-fenilacetamidas y sus derivados utiles como nuevos agentes antiangiogenicos.
EP1677791A4 (de) 2003-10-31 2007-08-15 Takeda Pharmaceutical Stickstoffhaltige kondensierte heterocyclische verbindungen

Also Published As

Publication number Publication date
US20070078140A1 (en) 2007-04-05
EP1937682B1 (de) 2015-08-12
WO2007041379A1 (en) 2007-04-12
JP2009510113A (ja) 2009-03-12
EP1937682A1 (de) 2008-07-02
US7547782B2 (en) 2009-06-16

Similar Documents

Publication Publication Date Title
NO20081454L (no) Met-kinaseinhibitorer
NO20081893L (no) 4-(3-aminopyrazol)pyrimidinderivater til anvendelse som tyrosin-kinaseinhibitorer i behandling av kreft
NO20080675L (no) P38-Map kinaseinhibitorer og metoder for deres anvendelse
NO20074634L (no) Substituerte heterocykler og deres anvendelse som CHK1-, PDK1- og PAK-inhibitorer
NO20092711L (no) Metoder for anvendelse av cyclopaminanaloger
NO20080965L (no) Cykloheksylaminisokinolonderivater som Rho-kinaseinhibotorer
NO20073859L (no) Pyrrolopyrazoler, potente kinaseinhibitorer
EA200900779A1 (ru) Производные дигидропиридина, полезные как ингибиторы протеинкиназы
NO20080150L (no) Inhibitorer av AKT-aktivitet
NO20073791L (no) Pyrazolylaminopyridinderivater anvendbare som kinaseinhibitorer
EA200901488A1 (ru) Замещенные имидазолопиридазины, как ингибиторы липидкиназы
MX2009011211A (es) Indoles sustituidos en la posicion 7 inhibidores de mci-1.
EA201100580A1 (ru) Имидазопиридазинкарбонитрилы, используемые в качестве ингибиторов киназы
NO20080981L (no) Nitrocatechol-derivater som COMT-inhibitorer
NO20092569L (no) Inhibitorer av Akt-aktivitet
EA201190158A1 (ru) Производные бензофуранила для применения в качестве ингибиторов глюкокиназы
NO20083918L (no) Dihydridiazepiner anvendelige som inhibitorer av proteinkinaser
NO20066081L (no) Kinazolinderivater som erbB-reseptortyrosinkinaser
NO20083923L (no) Pyrazolkinoloner er potente parp-inhibitorer
EA201170872A1 (ru) Ингибиторы протеинкиназы
EA200970447A1 (ru) Соединения и композиции в качестве ингибиторов протеинкиназы
EA200900983A1 (ru) Соединения и композиции в качестве ингибиторов киназы
WO2007079164A3 (en) Protein kinase inhibitors
NO20083267L (no) Azaindole inhibitorer av aurora kinaser
NO20090295L (no) Substituerte heteroarylderivater

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application